[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
11. Lee EY, Vargas SO, Sawicki GS, Boyer D, Grant FD, Voss SD: Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Pediatr Radiol; 2007 Dec;37(12):1278-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings.
  • In children, primary neoplasms of the tracheobronchial tree and lungs are rare; most are malignant.
  • Of the primary malignant pulmonary neoplasms arising in childhood, mucoepidermoid carcinoma accounts for approximately 10%.
  • Due to its well-confined local growth within the airway, mucoepidermoid carcinoma commonly produces respiratory symptoms from progressive tracheal or bronchial obstruction.
  • Mucoepidermoid tumor has minimal metastatic potential in children, and local resection alone is the current treatment of choice.
  • Early detection, diagnosis, and surgical resection of mucoepidermoid tumor are especially important in pediatric patients since the bulk of the remaining pulmonary parenchyma can be preserved, thereby decreasing the thoracic deformity and pulmonary functional morbidity.
  • Radiographic and CT imaging findings of bronchial mucoepidermoid carcinoma in children have been described in several case reports.
  • However, to the best of our knowledge, imaging findings of 2-((18)F)-fluoro-2-deoxy-D: -glucose positron emission tomography ((18)F-FDG PET) of mucoepidermoid carcinoma of the bronchus in pediatric patients have not been well established.
  • We report a mucoepidermoid carcinoma arising from the right upper lobe bronchus in a 15-year-old girl with an emphasis on the (18)F-FDG PET findings.
  • [MeSH-major] Bronchial Neoplasms / diagnostic imaging. Carcinoma, Mucoepidermoid / diagnostic imaging. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1369-73 [9574618.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):1361-7 [17056930.001]
  • [Cites] Pediatr Pulmonol. 2004 Jan;37(1):81-4 [14679495.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):395-7 [16977607.001]
  • [Cites] Comput Med Imaging Graph. 1990 Jul-Aug;14 (4):257-62 [2383865.001]
  • [Cites] Radiology. 2007 Feb;242(2):360-85 [17255408.001]
  • [Cites] J Pediatr Surg. 2005 Apr;40(4):E1-3 [15852255.001]
  • [Cites] Genes Chromosomes Cancer. 2006 May;45(5):470-81 [16444749.001]
  • (PMID = 17922270.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 K08 CA 093554
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Crain N, Nelson BL, Barnes EL, Thompson LD: Ceruminous gland carcinomas: a clinicopathologic and immunophenotypic study of 17 cases. Head Neck Pathol; 2009 Mar;3(1):1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ceruminal gland carcinomas are rare neoplasms confined to the skin lining the cartilaginous part of the external auditory canal.
  • Histologically, the tumors demonstrated a solid to cystic pattern, composed of an infiltrating glandular to cribriform arrangement of epithelial cells.
  • Histologic features included a dual cell population (although not the dominant histology), increased cellularity, moderate to severe nuclear pleomorphism, irregular nucleoli, increased mitotic figures (mean, 3/10 HPF), including atypical forms, and tumor necrosis (n = 2).
  • Tumors were divided into three types of adenocarcinoma based on pattern of growth and cell type (ceruminous, NOS [n = 12], adenoid cystic [n = 4], mucoepidermoid [n = 1]).
  • Metastatic adenocarcinoma or direct extension from salivary gland neoplasms are the principle differential considerations.
  • Eleven patients were alive or had died of unrelated causes without evidence of disease (mean, 11.2 years); six patients had died with disease (mean, 4.9 years), all of whom had developed local recurrence.
  • CONCLUSION: Ceruminous-type carcinomas, with the exception of ceruminous mucoepidermoid carcinoma, all demonstrated a dual cell population of basal myoepithelial-type cells and luminal apocrine cells.
  • [MeSH-major] Carcinoma / pathology. Ear Neoplasms / pathology. Ear, External / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Otorhinolaryngologic Surgical Procedures. Radiotherapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1973 Jun;65(6):909-13 [4350087.001]
  • [Cites] J Laryngol Otol. 1973 Dec;87(12):1201-10 [4357381.001]
  • [Cites] J Laryngol Otol. 1974 Apr;88(4):363-8 [4824672.001]
  • [Cites] Can J Otolaryngol. 1974;3(2):194-201 [4831936.001]
  • [Cites] Arch Otolaryngol. 1974 Nov;100(5):395-7 [4429488.001]
  • [Cites] Cancer. 1975 Sep;36(3):1072-6 [171051.001]
  • [Cites] J Laryngol Otol. 1975 Jul;89(7):707-20 [171328.001]
  • [Cites] Arch Otolaryngol. 1975 Nov;101(11):702-5 [1200915.001]
  • [Cites] Laryngoscope. 1977 Oct;87(10 Pt 1):1601-12 [198620.001]
  • [Cites] J Can Assoc Radiol. 1977 Dec;28(4):287-90 [303644.001]
  • [Cites] Cancer. 1978 Feb;41(2):545-53 [630537.001]
  • [Cites] Arch Otolaryngol. 1980 Jan;106(1):13-9 [6243462.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Sep;99(9 Pt 1):714-21 [2396807.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Dec;30(13):1034-7 [1714051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Feb;106(2):214-5 [1310808.001]
  • [Cites] Acta Morphol Hung. 1991;39(2):157-65 [1789146.001]
  • [Cites] J Laryngol Otol. 1992 Aug;106(8):727-32 [1328435.001]
  • [Cites] Pathology. 1992 Oct;24(4):315-9 [1337771.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 1993;114(1):49-52 [8191051.001]
  • [Cites] J Laryngol Otol. 1994 Aug;108(8):706-9 [7930929.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2873-83 [6291744.001]
  • [Cites] J Laryngol Otol. 1995 Mar;109(3):180-8 [7745330.001]
  • [Cites] Am J Dermatopathol. 1995 Apr;17(2):169-73 [8600783.001]
  • [Cites] J Laryngol Otol. 1996 Mar;110(3):249-51 [8730361.001]
  • [Cites] J Am Anim Hosp Assoc. 1996 Sep-Oct;32(5):448-52 [8875362.001]
  • [Cites] Indian J Cancer. 1997 Sep;34(3):139-42 [9491676.001]
  • [Cites] Br J Plast Surg. 1998 Jun;51(4):317-20 [9771352.001]
  • [Cites] J Laryngol Otol. 1957 Dec;71(12):824-31 [13491925.001]
  • [Cites] J Laryngol Otol. 1957 Dec;71(12):832-7 [13491926.001]
  • [Cites] Cancer. 1964 Jan;17:67-75 [14102073.001]
  • [Cites] J Otolaryngol. 1980 Dec;9(6):482-6 [6162967.001]
  • [Cites] J Laryngol Otol. 1981 Aug;95(8):843-8 [6267150.001]
  • [Cites] J Neurosurg. 1981 Dec;55(6):952-6 [7299469.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):153-61 [7039299.001]
  • [Cites] Laryngoscope. 1983 Mar;93(3):326-40 [6300574.001]
  • [Cites] Hiroshima J Med Sci. 1984 Mar;33(1):17-22 [6090347.001]
  • [Cites] J Am Acad Dermatol. 1984 Nov;11(5 Pt 1):841-7 [6096419.001]
  • [Cites] Laryngoscope. 1987 Feb;97(2):158-64 [3807618.001]
  • [Cites] Am J Otol. 1987 Nov;8(6):485-8 [3434612.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2292-302 [2804921.001]
  • [Cites] J R Soc Med. 1990 Jan;83(1):34-7 [2406442.001]
  • [Cites] J Laryngol Otol. 1999 Jun;113(6):578-80 [10605594.001]
  • [Cites] J Otolaryngol. 2001 Dec;30(6):373-7 [11771014.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jan;126(1):87-9 [11800656.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Apr;60(4):465-9 [11928113.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):834-7 [12117346.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 Sep-Oct;64(5):358-63 [12417781.001]
  • [Cites] J Laryngol Otol. 2003 Mar;117(3):202-4 [12648377.001]
  • [Cites] Am J Otolaryngol. 2003 Jul-Aug;24(4):274-7 [12884224.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2004 Dec;24(6):354-6 [15952686.001]
  • [Cites] Ear Nose Throat J. 2005 Sep;84(9):560-1 [16261754.001]
  • [Cites] Otol Neurotol. 2006 Jan;27(1):97-101 [16371854.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Oct;49(4):587-9 [17183866.001]
  • [Cites] Acta Otolaryngol. 2007 Mar;127(3):280-4 [17364365.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Dec;137(6):893-8 [18036417.001]
  • [Cites] J Neurosurg. 2008 Jan;108(1):97-104 [18173317.001]
  • [Cites] B-ENT. 2007;3(4):195-9 [18265725.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Jun;134(6):663-6 [18559737.001]
  • [Cites] Laryngoscope. 2008 Sep;118(9):1591-6 [18677277.001]
  • [Cites] Auris Nasus Larynx. 2003 Aug;30(3):287-90 [12927294.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):792-4 [14526681.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Sep-Oct;65(5):300-2 [14730188.001]
  • [Cites] J Laryngol Otol. 2003 Dec;117(12):951-4 [14738604.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):308-18 [15104293.001]
  • [Cites] Arch Otolaryngol. 1967 Jul;86(1):66-9 [6026961.001]
  • [Cites] Arch Dermatol. 1968 Oct;98(4):344-8 [4300211.001]
  • [Cites] Arch Otolaryngol. 1970 Jul;92(1):40-2 [4192890.001]
  • [Cites] J Laryngol Otol. 1970 Jul;84(7):743-5 [5432829.001]
  • [Cites] Pract Otorhinolaryngol (Basel). 1970;32(4):211-8 [5477506.001]
  • [Cites] Cancer. 1971 Sep;28(3):775-80 [4328926.001]
  • [Cites] Tex Med. 1970 Oct;66(10):56-9 [4335213.001]
  • [Cites] Cancer. 1972 May;29(5):1169-78 [5021609.001]
  • (PMID = 20596983.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807538
  • [Keywords] NOTNLM ; Adenoid cystic / Carcinoma / Ceruminal / Ceruminous / Ear / Gland / Immunohistochemistry / Mucoepidermoid / Prognosis
  •  go-up   go-down


23. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland tumors in survivors of childhood cancer.
  • BACKGROUND: There is an increased incidence of second malignant neoplasms in survivors of childhood cancers.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • Although, ionizing radiation has been demonstrated to increase the risk of developing a salivary gland neoplasm, there are few reports of salivary gland neoplasms occurring in patients treated for cancer in childhood.
  • RESULTS: Twelve survivors of childhood cancer developed a salivary gland neoplasm after completion of treatment.
  • The pathology of the salivary gland tumors were mucoepidermoid carcinoma (10), adenoid cystic carcinoma (1) , and pleomorphic adenoma (1).
  • All patients were treated with surgical excision of the primary tumor, and postoperative radiation was added in select patients.
  • Eleven patients were alive with no evidence of disease at last follow-up, and 1 patient was alive with clinical evidence of pulmonary metastasis.
  • CONCLUSION: Radiation and chemotherapy used to treat patients with childhood malignancies increases the risk of developing a second neoplasm of salivary gland origin.
  • The majority of these neoplasms are malignant; mucoepidermoid carcinoma occurs most frequently.
  • The treatment of these tumors includes surgical excision of the primary, with neck dissection in patients with clinical evidence of nodal metastasis, and postoperative radiation added for pathologies with adverse features.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


2
Advertisement
4. Hunt JL: Unusual thyroid tumors: a review of pathologic and molecular diagnosis. Expert Rev Mol Diagn; 2005 Sep;5(5):725-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual thyroid tumors: a review of pathologic and molecular diagnosis.
  • The most common thyroid neoplasms are either follicular derived (papillary, follicular and Hürthle cell lesions) or C-cell derived (medullary carcinoma).
  • The diagnosis of these tumors can usually be made at the histologic level, with immunohistochemical stains necessary in some circumstances.
  • Specific molecular mutations have been described that can be diagnostically useful or explain, in part, their pathogenesis, including the well-known Ret/PTC and PPARgamma-PAX8 translocations, point mutations in the Ret, Ras and BRAF genes, and loss of heterozygosity of multiple different tumor suppressor genes.
  • Some unusual tumors of the thyroid gland are more difficult to diagnose.
  • In examining these lesions, the pathologist may use the hematoxylin and eosin-stained morphology, coupled with an analysis of the immunohistochemical staining profiles and possibly analysis of the underlying molecular mutational patterns.
  • These less common thyroid tumors include tall cell and cribriform-morular variants of papillary carcinoma, hyalinizing trabecular tumor, mucoepidermoid and sclerosing mucoepidermoid carcinoma with eosinophilia, poorly differentiated (insular) carcinoma, and undifferentiated (anaplastic) carcinoma.
  • The diagnostic features of these rare tumors, including the histology, immunohistochemical expression profiles and the known molecular mutational profiles of each, are reviewed.
  • [MeSH-major] Molecular Diagnostic Techniques. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16149875.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 116
  •  go-up   go-down


25. Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, Forastiere AA: Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck; 2006 Mar;28(3):197-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers.
  • METHODS: Chemo-naive patients with histologically confirmed recurrent or metastatic carcinoma of salivary gland origin (mucoepidermoid, adenocarcinoma, or adenoid cystic) were eligible.
  • Eight partial responses were seen among the 31 patients with mucoepidermoid or adenocarcinoma histologic findings for a response rate of 26%.
  • CONCLUSION: Paclitaxel demonstrates moderate activity in salivary gland tumors of mucoepidermoid and adenocarcinoma histology.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / mortality. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 16470745.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA16116; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Neville HL, Hogan AR, Zhuge Y, Perez EA, Cheung MC, Koniaris LG, Thompson WR, Sola JE: Incidence and outcomes of malignant pediatric lung neoplasms. J Surg Res; 2009 Oct;156(2):224-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and outcomes of malignant pediatric lung neoplasms.
  • BACKGROUND: We sought to define current incidence trends and outcomes for children with lung and bronchus tumors.
  • METHODS: The SEER registry was queried from 1973 to 2004 for all patients with pulmonary tumors less than 20 y of age.
  • Most tumors arose in the lower lobe (37%), followed by the upper lobe (31.2%).
  • The most common histology was endocrine tumor (51.6%), followed by sarcoma (11%), and mucoepidermoid tumor (9%).
  • Endocrine and mucoepidermoid tumors had the best survival.
  • Multivariate analysis demonstrated nonsurgical treatment and nonendocrine tumor histology to be independent prognostic factors of death.
  • Several factors, including nonsurgical treatment and nonendocrine tumors confer a poor prognosis.
  • [MeSH-major] Lung Neoplasms / epidemiology. SEER Program

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19631347.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Takahama Junior A, Almeida OP, Kowalski LP: Parotid neoplasms: analysis of 600 patients attended at a single institution. Braz J Otorhinolaryngol; 2009 Jul-Aug;75(4):497-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid neoplasms: analysis of 600 patients attended at a single institution.
  • Salivary gland tumors are rare, generally benign and affect mainly the parotid gland.
  • AIM: The purpose of this study was to retrospectively analyze all cases of parotid tumors treated at our institution from 1953 to 2003.
  • METHODS: All patients with primary parotid tumors were selected; clinical and histopathological data were analyzed and described.
  • RESULTS: 600 cases of parotid tumors were selected; 369 were benign and 231 were malignant.
  • Pleomorphic adenoma was the most frequent benign tumor.
  • The most common malignant tumor was the mucoepidermoid carcinoma.
  • Adjuvant therapy -- mainly radiotherapy -- was used in some cases with malignant tumors.
  • The incidences of local, regional and distant recurrences of malignant tumors were 10%, 8% and 9%.
  • CONCLUSION: Patients with parotid tumors treated at our institution were mainly adults, with marginally more female patients.
  • Benign tumors were mostly the pleomorphic adenoma, which were more frequent than malignancies.
  • Adjuvant therapy, mainly radiotherapy, was used in selected malignant cases.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Carcinoma, Mucoepidermoid / surgery. Parotid Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19784416.001).
  • [ISSN] 1808-8686
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


28. Khandekar MM, Kavatkar AN, Patankar SA, Bagwan IB, Puranik SC, Deshmukh SD: FNAC of salivary gland lesions with histopathological correlation. Indian J Otolaryngol Head Neck Surg; 2006 Jul;58(3):246-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate utility of FNAC in salivary gland lesions.Back ground: Salivary gland lesions form about 2-6.5% of all head and neck neoplasms in adults.
  • They are easily accessible for FNAC (Fine Needle Aspiration Cytology) and risks of fistula formation or tumour implantation are low compared surgical biopsy.
  • Also, cytology can provide a distinction between asalivary and non salivary lesion, benign and malignant lesions so also specific and non specific inflammation.
  • RESULTS: 80% of the lesions were neoplastic (61% benign, 31% malignant) and 20% were neoplastic.
  • Pleomorphic adenoma was the most frequent benign neoplasm while mucoepidermoid carcinoma was the most frequent malignant lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23120304.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450424
  • [Keywords] NOTNLM ; FNAC / Salivary Gland / Salivary Gland Tumours
  •  go-up   go-down


29. Anzick SL, Chen WD, Park Y, Meltzer P, Bell D, El-Naggar AK, Kaye FJ: Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Genes Chromosomes Cancer; 2010 Jan;49(1):59-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions.
  • The CRTC1-MAML2 fusion oncogene underlies the etiology of mucoepidermoid salivary gland carcinoma (MEC) where it confers a favorable survival outcome as compared with fusion-negative MEC.
  • While these analyses suggested that detection of CRTC1-MAML2 serves as a useful prognostic biomarker, we recently identified outlier cases of fusion-positive MEC associated with advanced-staged lethal disease.
  • To identify additional genetic alterations that might cooperate with CRTC1-MAML2 to promote disease progression, we performed a pilot high-resolution oligonucleotide array CGH (aCGH) and PCR-based genotyping study on 23 MEC samples including 14 fusion-positive samples for which we had clinical outcome information.
  • We did not detect either activating EGFR mutations, nor copy number gains at the EGFR or ERBB2 loci as poor prognostic features for fusion-positive MEC in any of the tumor specimens.
  • Prospective studies with larger case series will be needed to confirm that combined CRTC1-MAML2 and CDKN2A genotyping will optimally stage this disease.
  • [MeSH-major] Carcinoma, Mucoepidermoid / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA-Binding Proteins / genetics. Gene Deletion. Nuclear Proteins / genetics. Oncogene Proteins, Fusion. Transcription Factors / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comparative Genomic Hybridization. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Genotype. Humans. Male. Middle Aged. Pilot Projects. Polymerase Chain Reaction. Prognosis. Receptor, Epidermal Growth Factor. Receptor, ErbB-2. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2009 Jan;63(1):159-60 [18992960.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):89-95 [7558818.001]
  • [Cites] Hum Pathol. 2009 Jun;40(6):854-60 [19269006.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):835-43 [19092631.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):42-55 [11237522.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1211-6 [7566983.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1217-24 [9529011.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):224-31 [9917133.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):202-5 [15729701.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):771-6 [15959912.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7137-44 [16103063.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Genes Chromosomes Cancer. 2006 May;45(5):470-81 [16444749.001]
  • [Cites] J Cell Physiol. 2006 Jun;207(3):654-9 [16447252.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3902-7 [16818685.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6128-32 [16652146.001]
  • [Cites] Adv Anat Pathol. 2006 Nov;13(6):293-307 [17075295.001]
  • [Cites] Curr Oncol Rep. 2007 Mar;9(2):134-8 [17288880.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Apr;36(4):350-3 [17223311.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):708-15 [17437281.001]
  • [Cites] Am J Dermatopathol. 2007 Oct;29(5):457-61 [17890914.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Mar;47(3):203-6 [18050304.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 15;180(2):135-9 [18206539.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):414-20 [18268126.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1118-28 [18337602.001]
  • [Cites] Lung Cancer. 2008 Jul;61(1):30-4 [18192072.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):90-2 [18542074.001]
  • [Cites] Am J Dermatopathol. 2009 May;31(3):236-47 [19384064.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1242-6 [10534174.001]
  • [Cites] Mod Pathol. 2008 Sep;21(9):1168-75 [18587327.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):835-45 [11420454.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6908-14 [12362273.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):208-13 [12539049.001]
  • [Cites] Exp Cell Res. 2004 Jan 1;292(1):21-8 [14720503.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):205-10 [15269296.001]
  • [Cites] J Surg Oncol. 1991 Feb;46(2):100-6 [1992215.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • (PMID = 19827123.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC007256-19
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ NIHMS143697; NLM/ PMC2783528
  •  go-up   go-down


30. Bell D, Luna MA, Weber RS, Kaye FJ, El-Naggar AK: CRTC1/MAML2 fusion transcript in Warthin's tumor and mucoepidermoid carcinoma: evidence for a common genetic association. Genes Chromosomes Cancer; 2008 Apr;47(4):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CRTC1/MAML2 fusion transcript in Warthin's tumor and mucoepidermoid carcinoma: evidence for a common genetic association.
  • The t(11;19) translocation and its CRTC1/MAML2 fusion transcript have been identified in several examples of both Warthin's tumor and mucoepidermoid carcinoma and are believed to be associated with the development of a subset of these tumors.
  • To determine whether Warthin's tumor and mucoepidermoid carcinoma are genetically related, we used reverse transcriptase-polymerase chain reaction and DNA sequencing to analyze microdissected components of three tumors consisting of Warthin's tumor and mucoepidermoid carcinoma.
  • We also investigated a metastatic melanoma to Warthin's tumor and a Warthin's carcinoma of the parotid gland for comparison.
  • The fusion transcript was identified in both Warthin's tumor and matching mucoepidermoid carcinoma components of all three tumors, in the Warthin's carcinoma, and in the Warthin's tumor component but not in the metastatic melanoma.
  • The results provide evidence for a link between the t(11;19) fusion gene and the development of a subset of Warthin's tumors with concurrent mucoepidermoid carcinoma and possible malignant transformation to Warthin's carcinoma.
  • [MeSH-major] Adenolymphoma / genetics. Carcinoma, Mucoepidermoid / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Parotid Neoplasms / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Melanoma / genetics. Melanoma / secondary. Middle Aged. RNA, Messenger. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • Genetic Alliance. consumer health - Warthin's tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18181164.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / Transcription Factors
  •  go-up   go-down


31. Gaissert HA, Grillo HC, Shadmehr MB, Wright CD, Gokhale M, Wain JC, Mathisen DJ: Uncommon primary tracheal tumors. Ann Thorac Surg; 2006 Jul;82(1):268-72; discussion 272-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon primary tracheal tumors.
  • BACKGROUND: Primary tracheal tumors other than adenoid cystic or squamous cell carcinoma are uncommon and have a heterogeneous histologic appearance.
  • METHODS: A retrospective analysis was performed of uncommon tracheal tumors among 360 primary tracheal tumors seen over 40 years, excluding adenoid cystic and squamous cell carcinoma.
  • RESULTS: Of 90 patients, 34 (38%) had benign tumors and 56 malignant: 11 carcinoid tumors, 14 mucoepidermoid carcinomas, 13 sarcomas, 15 nonsquamous bronchogenic carcinomas, 2 lymphomas, and 1 melanoma.
  • Dyspnea was the most common symptom in benign tumors and hemoptysis in malignant tumors.
  • After resection, survival at 10 years was 94% for benign and 83% for carcinoid tumors, and at 5 years survival was 60% for bronchogenic carcinoma, 100% for mucoepidermoid tumors, and 78% for sarcomas.
  • CONCLUSIONS: Surgical resection of uncommon primary tracheal tumors alleviates airway obstruction, is curative in patients with benign or slow-growing malignant lesions, and prolongs survival in highly malignant lesions.
  • [MeSH-major] Tracheal Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bronchi / surgery. Bronchoscopy. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Hospital Mortality. Humans. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Laryngectomy. Life Tables. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16798228.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Khadilkar UN, Kumar S, Prabhu PP, Kamath M: Mucoepidermoid carcinoma of lung: a case report. Indian J Pathol Microbiol; 2007 Jul;50(3):560-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of lung: a case report.
  • Mucoepidermoid lung tumours are uncommon neoplasms comprising of 0.2% of all the lung tumours and historically included under the term bronchial adenomas.
  • This is a case report of a bronchial tumour in the hilar region present since 3 years.
  • The neoplasm could be easily classified as a mucoepidermoid tumour of low malignant potential, as it resembled the histologically identical lesion in the main salivary glands.
  • The case is reported for its rarity and for the histological evaluation of the malignant potential in an apparently clinically benign neoplasm.
  • [MeSH-major] Carcinoma, Mucoepidermoid / diagnosis. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883135.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


33. Friedrich RE, Klapdor R, Bartel-Friedrich S: Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers. Anticancer Res; 2007 Jul-Aug;27(4A):2099-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers.
  • Mucoepidermoid carcinoma (MEC) of the salivary gland is a rare entity.
  • A distinction of 2 variants has been proposed: the low-grade tumor with a favourable prognosis and the high-grade tumor with a poor prognosis.
  • This excellent prognosis might contribute to the unacceptable retention of the term "mucoepidermoid tumor" in the medical terminology, even in current medical textbooks.
  • We describe the rapid fatal outcome of a patient with MEC in order to emphasize the malignant characteristics of this tumor and the possible application of tumor markers for the diagnosis of metastasizing MEC.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Mucoepidermoid / blood. Salivary Gland Neoplasms / blood
  • [MeSH-minor] Bone Neoplasms / secondary. Disease Progression. Fatal Outcome. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Salivary Glands, Minor / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649828.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Luna MA: Salivary mucoepidermoid carcinoma: revisited. Adv Anat Pathol; 2006 Nov;13(6):293-307
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary mucoepidermoid carcinoma: revisited.
  • Mucoepidermoid carcinoma (MEC) is a malignant epithelial neoplasm composed of varying proportions of mucous, epidermoid, intermediate, columnar, and clear cells and often demonstrates prominent cystic growth.
  • Because even low-grade neoplasms may metastasize, the term mucoepidermoid tumor is inappropriate.
  • The 3-level grading approach to tumor classification has found general acceptance among pathologists; differences in biologic behavior can be demonstrated even though clinical stage has become a better prognosticator.
  • We describe these new schemes, the histologic variants of MEC, and the ancillary methods that allow for further stratification of patients with MEC, especially for patients with grade 2 tumors, which have a variable and unpredictable clinical course.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075295.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down






Advertisement